SciSparc Ltd., a biopharmaceutical company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Tel Aviv, Israel, submitted the request on September 3, 2024, with the aim for the Registration Statement to become effective on September 5, 2024, at 4:15 p.m. Eastern Time. This acceleration would facilitate SciSparc's proposed public offering of securities as detailed in the Registration Statement. The company has acknowledged its understanding of the responsibilities under the Securities Act in relation to the public offering. SciSparc has also requested that the SEC confirm the effectiveness of the Registration Statement both by telephone and in writing.

SciSparc Ltd., a biopharmaceutical company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Tel Aviv, Israel, submitted the request on September 3, 2024, with the aim for the Registration Statement to become effective on September 5, 2024, at 4:15 p.m. Eastern Time. This acceleration would facilitate SciSparc's proposed public offering of securities as detailed in the Registration Statement. The company has acknowledged its understanding of the responsibilities under the Securities Act in relation to the public offering. SciSparc has also requested that the SEC confirm the effectiveness of the Registration Statement both by telephone and in writing.